FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.(Image credit: Maddie Meyer)
Reported by 1 outlet — NPR News. See all sources ↓
The FDA is reviewing Moderna's mRNA-based flu vaccine. If approved, it would be the first flu shot using mRNA technology. A decision is expected soon and could impact the biotech sector.
Why it matters
An mRNA flu shot could offer stronger or faster protection against the flu. It also shows how mRNA technology, used in COVID vaccines, may expand to other diseases.
- What type of technology does Moderna's new flu shot use?
- It uses messenger RNA (mRNA) technology.
- Why is the FDA's decision important for the biotech industry?
- Approval could encourage more mRNA vaccines and affect investments in biotech.
How outlets are framing the same story
Here's how each outlet is covering the story — compare their headlines and timing at a glance.
All outlets frame the story the same way, focusing on the FDA's pending decision about Moderna's mRNA flu shot.
- Coverage card1 outlet1CoverageScouting report
FDA weighs a new kind of flu shot based on technology RFK Jr. has questioned
Sources1TypeCoverageNPR News